pipeline v2.jpg

PRK-101 is a first-in-class investigational drug to treat patients with acute and chronic pain.  It has a unique MOA and has demonstrated efficacy in multiple Phase 2 and Phase 3 clinical studies across several nociceptive and neuropathic indications as well as a superior safety profile.  We believe PRK-101 could provide a safer and less addicitive option for many pain patients and intend to develop it broadly for multiple indications.